NASDAQ:CHRS - Coherus Biosciences Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $14.25 +0.07 (+0.49 %) (As of 04/24/2019 02:01 PM ET)Previous Close$14.18Today's Range$13.55 - $14.3452-Week Range$8.32 - $20.66Volume37,671 shsAverage Volume811,803 shsMarket Capitalization$988.08 millionP/E RatioN/ADividend YieldN/ABeta3.62 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Coherus BioSciences, Inc., a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States. Its clinical-stage product candidates include immunology, anti-tumor necrosis factor biosimilar candidates, CHS-1420 for adalimumab and CHS-0214 for etanercept, which has completed Phase III clinical programs; ophthalmology biosimilar candidates, CHS-3351 for ranibizumab and CHS-2020 for aflibercept that is in preclinical development; and CHS-131, small molecule therapeutic candidate and other metabolic conditions. Coherus BioSciences, Inc. has collaboration and license agreements with Daiichi Sankyo Company, Limited; Baxalta Incorporated; Baxalta US Inc.; Baxalta GmbH; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California. Receive CHRS News and Ratings via Email Sign-up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CHRS Previous Symbol CUSIPN/A CIK1512762 Webwww.coherus.com Phone650-649-3530Debt Debt-to-Equity Ratio8.29 Current Ratio2.54 Quick Ratio2.49Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.56 million Price / Sales633.39 Cash FlowN/A Price / Cash FlowN/A Book Value($0.57) per share Price / Book-25.00Profitability EPS (Most Recent Fiscal Year)($3.22) Net Income$-209,340,000.00 Net MarginsN/A Return on Equity-2,572.60% Return on Assets-150.15%Miscellaneous Employees232 Outstanding Shares69,339,000Market Cap$988.08 million Next Earnings Date5/9/2019 (Confirmed) OptionableOptionable Coherus Biosciences (NASDAQ:CHRS) Frequently Asked Questions What is Coherus Biosciences' stock symbol? Coherus Biosciences trades on the NASDAQ under the ticker symbol "CHRS." How were Coherus Biosciences' earnings last quarter? Coherus Biosciences Inc (NASDAQ:CHRS) issued its quarterly earnings data on Thursday, February, 28th. The biotechnology company reported ($0.92) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.82) by $0.10. View Coherus Biosciences' Earnings History. When is Coherus Biosciences' next earnings date? Coherus Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, May 9th 2019. View Earnings Estimates for Coherus Biosciences. What price target have analysts set for CHRS? 5 analysts have issued 1-year price targets for Coherus Biosciences' stock. Their forecasts range from $25.00 to $45.00. On average, they anticipate Coherus Biosciences' stock price to reach $30.20 in the next year. This suggests a possible upside of 111.9% from the stock's current price. View Analyst Price Targets for Coherus Biosciences. What is the consensus analysts' recommendation for Coherus Biosciences? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Coherus Biosciences in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Coherus Biosciences. What are Wall Street analysts saying about Coherus Biosciences stock? Here are some recent quotes from research analysts about Coherus Biosciences stock: 1. According to Zacks Investment Research, "Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701 which has completed a Phase I study for the treatment of breast cancer patients. Coherus Biosciences, Inc. is headquartered in Redwood City, California. " (4/9/2019) 2. Maxim Group analysts commented, "CHRS shares are trading up ~12% on better than expected preliminary 1Q19 net sales of $36M-$38M for UDENYCA (initial launch 1/3). These initial figures suggest that uptake is progressing, in our view, faster than anticipated considering consensus estimates for FY19 were ~$70M-$80M as of the 4Q18 earnings call (2/28/19). The company will provide greater detail on its 1Q19 earnings call scheduled for 5/9/19." (4/8/2019) Has Coherus Biosciences been receiving favorable news coverage? Press coverage about CHRS stock has been trending very positive on Wednesday, InfoTrie reports. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Coherus Biosciences earned a media sentiment score of 3.3 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. Who are some of Coherus Biosciences' key competitors? Some companies that are related to Coherus Biosciences include China Biologic Products (CBPO), argenx (ARGX), Ablynx (ABLYF), Allogene Therapeutics (ALLO), Repligen (RGEN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Acceleron Pharma (XLRN), Crispr Therapeutics (CRSP), Regenxbio (RGNX), Aerie Pharmaceuticals (AERI), Audentes Therapeutics (BOLD), Orchard Therapeutics (ORTX), Alector (ALEC) and Atara Biotherapeutics (ATRA). What other stocks do shareholders of Coherus Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus Biosciences investors own include Chembio Diagnostics (CEMI), Halozyme Therapeutics (HALO), Intelsat (I), Exelixis (EXEL), Fossil Group (FOSL), Apollo Global Management (APO), Bank of America (BAC), First Data (FDC), Associated British Foods (ABF) and Chaarat Gold (CGH). Who are Coherus Biosciences' key executives? Coherus Biosciences' management team includes the folowing people: Mr. Dennis M. Lanfear, Chairman, Pres & CEO (Age 64)Dr. Jean-Frédéric Viret, Chief Financial Officer (Age 53)Dr. Peter K. Watler, Chief Technical Officer (Age 57)Dr. V. Bryan Lawlis Jr., Science Director, Director & Member of Supervisory Board (Age 67)Mr. Vincent R. Anicetti, Chief Operating Officer (Age 64) Who are Coherus Biosciences' major shareholders? Coherus Biosciences' stock is owned by a number of of retail and institutional investors. Top institutional investors include Pier Capital LLC (0.76%), Rhenman & Partners Asset Management AB (0.65%), Boston Advisors LLC (0.09%) and Ellis Investment Partners LLC (0.02%). Company insiders that own Coherus Biosciences stock include Alan C Herman, Barbara K Finck, Dennis M Lanfear, James Healy and Jean-Frederic Viret. View Institutional Ownership Trends for Coherus Biosciences. Which major investors are selling Coherus Biosciences stock? CHRS stock was sold by a variety of institutional investors in the last quarter, including Pier Capital LLC. Company insiders that have sold Coherus Biosciences company stock in the last year include Barbara K Finck, Dennis M Lanfear, James Healy and Jean-Frederic Viret. View Insider Buying and Selling for Coherus Biosciences. Which major investors are buying Coherus Biosciences stock? CHRS stock was acquired by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Boston Advisors LLC and Ellis Investment Partners LLC. View Insider Buying and Selling for Coherus Biosciences. How do I buy shares of Coherus Biosciences? Shares of CHRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Coherus Biosciences' stock price today? One share of CHRS stock can currently be purchased for approximately $14.25. How big of a company is Coherus Biosciences? Coherus Biosciences has a market capitalization of $988.08 million and generates $1.56 million in revenue each year. The biotechnology company earns $-209,340,000.00 in net income (profit) each year or ($3.22) on an earnings per share basis. Coherus Biosciences employs 232 workers across the globe. What is Coherus Biosciences' official website? The official website for Coherus Biosciences is http://www.coherus.com. How can I contact Coherus Biosciences? Coherus Biosciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The biotechnology company can be reached via phone at 650-649-3530 or via email at [email protected] MarketBeat Community Rating for Coherus Biosciences (NASDAQ CHRS)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 280 (Vote Outperform)Underperform Votes: 278 (Vote Underperform)Total Votes: 558MarketBeat's community ratings are surveys of what our community members think about Coherus Biosciences and other stocks. Vote "Outperform" if you believe CHRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CHRS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/24/2019 by MarketBeat.com StaffFeatured Article: What are the risks of holding treasury bonds?